Company intelligence / Profile preview

Nowicky Pharma

Ownership: Private
Employees: ~4
Development stage: Commercial

Overview

Nowicky Pharma produces Ukrain (also called celandine), a semi-synthetic substance derived from the plant Chelidonium majus (greater celandine). The drug has been approved in Belarus since February 1996, but has been prohibited from being imported, manufactured, and marketed in Austria due to lack of proven efficacy, quality, and safety. According to the company, Ukrain accumulates in cancer cells within minutes after administration and triggers apoptosis in cancer cells while leaving healthy cells undamaged at therapeutic doses.

Therapeutic areas: Oncology
Modalities: Small molecule drug
Industry: Biotech

Drug pipeline

1 asset

Ukrain

Unknown

Beyond the preview

Go deeper on Nowicky Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nowicky Pharma.

Explore the full profile